Universal Navigation

Member Log In

Access exclusive information available only to members of the AAN.

Forgot your password? Recover now

Contact Us

Not yet a member?

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

  • Online education resources at no additional cost
  • Discounts on Annual Meeting registration
  • Guidelines and publications including Neurology® journal
  • A network of 34,000+ neurologists and neuroscience professionals
  • The latest research and news affecting neurology

Join Now See All Benefits

C29 - Multiple Sclerosis Overview II: Clinical Advances

Event Time: Saturday May 4, 2019 1:30 pm to 3:30 pm
Topic(s): MS and CNS Inflammatory Disease, Foundations in Clinical Neurology for APPs
Director(s): Scott Newsome DO, FAAN
Description: It is extremely important for clinicians treating MS to enhance their knowledge base about the changing landscape of the MS disease-modifying therapies (DMTs). Making treatment decisions for an individual MS patient is a daunting task and the individualized patient benefit-risk assessment becomes increasingly difficult as new therapies emerge. Furthermore, if these therapies become available, clinicians need to have a full understanding of their benefit-risk profiles. Faculty will review the efficacy and safety profiles of current and late-stage emerging MS DMTs. It is equally challenging to define what constitutes optimal and suboptimal response to DMTs for an individual patient. Moreover, it is critical for clinicians to be able to recognize short-term clinical and paraclinical factors that may help identify patients at high risk for long-term disability. Faculty will review key considerations in MS clinical practice to address the above challenges in both didactic and case-based formats. This program complements Multiple Sclerosis Overview I: Clinical Pearls, but covers independent topics.
Completion Message: Participants should feel more confident in prescribing and monitoring multiple sclerosis (MS) disease-modifying therapies (DMTs) as it relates to their efficacy and safety profiles, and develop a better understanding of key considerations in clinical practice; become familiar with late-stage DMTs that have a strong potential of getting approved for use in MS; and be able to recognize what factors put an MS patient at risk for long-term disability and when to consider switching therapies.
CME Credits: 2
Core Competencies: Patient Care, Medical Knowledge

Ready to register for the 2019 AAN Annual Meeting?

Register Now

Related Courses

Footer